You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg VirusSBC: EVRYS BIO LLC Topic: CBD18A002
In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare ApplicationsSBC: GeneCapture, Inc. Topic: CBD15C001
GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: CFD Research Corporation Topic: CBD18A001
In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense